Advertisement
Home Tags Prescription Drugs

Tag: Prescription Drugs

Distribution of Neurologists Across U.S. Varies Widely

Women Must Get Abortion Pill in Person: U.S. Supreme Court

0

Similar in-person rules for other medications have been suspended during the pandemic

WHO: Remdesivir Not Advised for Hospitalized COVID-19 Patients

Experimental Drug for Alzheimer Disease Shows Promise

0

After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques

Lipid Screen

Hydroxychloroquine Level Tied to Thrombosis Risk in Lupus

0

Rate of thrombotic events lower for patients with mean HCQ blood levels >1,068 versus <648 ng/mL

Tool Could Optimize Antibiotic Prescribing for UTI

Sitagliptin Promising Addition for Preventing Acute GVHD

0

Low incidence of grade II to IV acute GVHD seen in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation

Drug Makers Raise Prices on 500 Prescription Drugs

0

AbbVie, Bristol Myers Squibb, GlaxoSmithKline, and Pfizer among companies raising their prices by a median of 4.6 percent

Okada Test Article

Euglycemic DKA ID’d in T2DM Patients With COVID-19

0

Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS-CoV-2 infection

Jaw Osteonecrosis Tied to Treatment for Bone Metastases

0

Cancer type, oral health, and frequency of dosing for zoledronic acid linked to risk for osteonecrosis of the jaw

Factors Associated With Suicide in Leukemia Identified

Oral Azacitidine Benefits Some Older Adults With AML

0

Overall, relapse-free survival prolonged among older patients in first remission after chemo who receive CC-486 versus placebo

Incidence of Restless Leg Syndrome High in Pregnancy

Seizure Frequency Not Up in Pregnancy for Women With Epilepsy

0

Changes in doses of antiepileptic drugs occurred more often in pregnant women than in nonpregnant controls

Pembrolizumab Slows MSI-H-dMMR Metastatic CRC

Triple Treatment Combo Beneficial in BRAF-Mutant CRC

0

Irinotecan, cetuximab, and vemurafenib improve progression-free survival in BRAFV600E-mutated colorectal cancer